ABVC BioPharma(us:ABVC)

    0.5295

    +1.05%

    Updated on 2024-12-23

    Open:0.5100
    Close:0.5295
    High:0.5388
    Low:0.4900
    Pre Close:0.5240
    Volume:92280.00
    Amount:47639.81
    Turnover:0.71%
    Shares:12.98M
    MarketCap:6.87M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-30132204021.83%523
    2024-03-31102544692.38%242
    2023-12-31101107201.39%133
    2023-09-3012767991.59%335
    2023-06-3011588510.18%224
    2023-03-31116611352.00%243
    2022-12-31136031481.84%237
    2022-09-30126506211.99%722
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Chase Investment Counsel Corp1783771.67%178377
    2024-03-31Vanguard Group Inc469470.44%1970072.30%
    2024-03-31Geode Capital Management, Llc220000.21%252012.94%
    2024-03-31Bank Of America Corp /De/44400.04%4440
    2024-03-31Tower Research Capital Llc (Trc)25200.02%1942335.99%
    2024-03-31Spotlight Asset Group, Inc.1000.00%0
    2024-03-31Wells Fargo & Company/Mn480.00%28140.00%
    2024-03-31Royal Bank Of Canada370.00%0
    2024-03-31Citadel Advisors Llc0-27158
    2024-03-31Renaissance Technologies Llc0-36100

    About

    ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
    Address:44370 Old Warm Springs Boulevard

    Market Movers